Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Expanding its portfolio further into cardiovascular health, Marlborough medical device manufacturer Boston Scientific has ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Boston Scientific’s Farapulse system won FDA approval in January, shortly after Medtronic secured the first FDA approval for its PFA ablation device, Pulseselect. PFA is a new treatment for AFib ...

Boston Scientific (NYSE:BSX) shares were down 5% in morning trading Wednesday following news that the company has paused a study for its new FARAPULSE Pulse Field Ablation system due to unforeseen ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third quarter powered by the launch of its Farapulse system for atrial ...

Boston Scientific noted that the technologies are compatible exclusively with its existing cardiac mapping technology and the company's latest offering, the OPAL HDx Mapping System. The company ...